Bio-Techne Corporation: Business Overview, Financials & Competitive Analysis
Bio-Techne Corporation scores 7/10 on the AskCyborg Cyborg Score (Solid). Indispensable "picks and shovels" provider with growing revenue in cell therapy markets and broad customer diversification across pharma, biotech, and academia. The company achieved 5% organic revenue growth to approximately $1.22 billion in fiscal year 2025, with Q2 FY2025 showing 9% organic revenue increase and adjusted EPS of $0.42, driven.
What is Bio-Techne Corporation's industry? Bio-Techne Corporation (bio-techne.com) operates in Medical Devices. AskCyborg classifies Bio-Techne Corporation under Medical Devices in its company registry.
Bio-Techne Corporation is a global biotechnology company specializing in the development, manufacturing, and supply of high-quality reagents, analytical instruments, and precision diagnostics for life sciences researc...
Cyborg Score thesis
Indispensable "picks and shovels" provider with growing revenue in cell therapy markets and broad customer diversification across...
Read the full analyst-debate transcript →Get the Latest Bio-Techne Corporation Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeBio-Techne Corporation Overview
Pro stress-test →Bio-Techne Corporation is a global biotechnology company specializing in the development, manufacturing, and supply of high-quality reagents, analytical instruments, and precision diagnostics for life sciences research, therapeutic development, and clinical applications, headquartered in Minneapolis, Minnesota. The company operates through key segments including Protein Sciences—encompassing proteins, antibodies, and immunoassays—and Diagnostics & Spatial Biology, focusing on advanced tools for spatial phenotyping and cell therapy workflows.
Strategic Profile
Pro stress-test →Bio-Techne has solidified its position as a "picks and shovels" provider for the biotechnology industry, ensuring that researchers have the high-quality proteins and antibodies necessary for reproducible science. The company operates a portfolio exceeding 500,000 products with over 3,100 employees across 34 locations worldwide and serves end markets such as pharmaceuticals, biotechnology, academia, and diagnostics.
Competitive Landscape
Pro stress-test →Bio-Techne competes in the life sciences tools and reagents market against established players including Thermo Fisher Scientific, Merck KGaA, and Abcam. The company differentiates through its comprehensive product portfolio exceeding 500,000 items and specialized expertise in spatial biology and cell therapy applications. Its positioning as a pure-play reagents and diagnostics provider contrasts with larger, more diversified life sciences conglomerates.
Industry Context
Bio-Techne Corporation operates in Medical Devices.
Key facts
Founded: 1976 · Headquarters: Minneapolis, US · Employees: 3,100 · Revenue: $1.22B · Market cap: N/A